newwin
Luciann Nguyen
Settings
← Accounts
academic

Henan Cancer Hospital

48
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Henan Cancer Hospital

New trial — RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors

New trialNCT06545201
48/100
Opportunity
Commercial fit6/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1 trial NCT06545201 posted by Henan Cancer Hospital: "RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors". New trial on a phase 1 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 760 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT06545201
RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
phase 1
mol. elig.